Outsmarting the Heart: Device Therapy Targeting the Neurohormonal Pathway in Heart Failure Patients
Published 08 May 2025
Barostim is a novel device therapy that works with GDMT to target the neurohormonal pathways responsible for heart failure progression and symptoms. In this symposium, a multi-disciplinary faculty discusses unmet needs with GDMT and device therapies in class II/III heart failure patients and reviews the Barostim implant procedure, clinical data, patient selection, and real world strategies for incorporating Barostim into a comprehensive heart failure program.
The content of this recording was developed entirely by our industry partner, CVRx. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.